Randomized and double-blind studies - Demands and reality as demonstrated by two examples of mistletoe research

Forschende Komplementarmedizin und Klassische Naturheilkunde

Volumn 11, Issue SUPPL. 1, 2004, Pages 18-22

  Rostock, M ^a,b   Huber, R ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Complementary cancer treatments; Double blind, placebo controlled trial; Mistletoe therapy; Non randomized trial; Randomized controlled trial (RCT)

Indexed keywords

PLACEBO;

CANCER CHEMOTHERAPY; CANCER PATIENT; CONFERENCE PAPER; HUMAN; IMMUNOLOGICAL PROCEDURES; IMMUNOLOGY; INFLAMMATION; MEDICAL RESEARCH; PILOT STUDY; PROSPECTIVE STUDY; PUBLISHING; QUALITY OF LIFE; RANDOMIZATION; RELIABILITY;

BREAST NEOPLASMS; COMPLEMENTARY THERAPIES; DOUBLE-BLIND METHOD; HUMANS; LECTINS; MISTLETOE; PHYTOTHERAPY; PLANT EXTRACTS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 4644366156     PISSN: 14247364     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080571     Document Type: Conference Paper

References (14)

1. Diggle PJ, Liang KY, Zeger SL: Analysis of Longitudinal Data. Oxford, Clarendon Press, 1994.
2. Steuer-Vogt MK, Bonkowsky V, Ambrosch P, Scholz M, Neiß A, Strutz J, Hennig M, Lenarz T, Arnold W: The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: A randomised controlled clinical trial. Eur J Cancer 2001;37:23-31.
3. Semiglasov VF, Stepula VV, Dudov A, Lehmacher W, Mengs U: The standardised Mistletoe Extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: A randomized, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res 2004;24:1291-1300.
4. Weis J, Bartsch HH, Hennies F, Rietschel M, Heim M, Adam G, Gärtner U, Ammon A: Complementary medicine in cancer patients: demand, patient attitudes and psychological beliefs. Onkologie 1998;21:144-149.
5. Boon H, Stewart M, Kennard MA, Gray R, Sawka C, Brown JB, McWilliam C, Gavin A, Baron RA, Aaron D, Haines-Kamka T: Use of complementary/ alternative medicine by breast cancer survivors in Ontario: prevalence and perceptions. J Clin Oncol 2000;18:2515-2521.
6. Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE: Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 2000;18:2505-2514.
7. Schwabe U, Paffrath D: Arzneiverordnungsreport 2003. Heidelberg, Springer, 2003, pp 537-552.
8. Huber R, Lüdtke R, Beiser I, Koch D: Coping strategies and the request for a consultation on complementary and alternative medicine - a cross-sectional survey of patients in a psychosomatic and three medical departments of a German university hospital. Forsch Komplementärmed Klass Naturheilkd 2004;11:207-211.
9. Spielberger I, Bonn, personal communication.
10. Hoffmann C, Stange R, Berlin, personal communication.
11. Gerhard I, Abel U, Loewe-Mesch A, Huppmann S, Kuehn JJ: Problematik randomisierter Studien in der Komplementärmedizin dargestellt am Beispiel der Misteltherapie bei Patientinnen mit Mammakarzinom. Forsch Komplementärmed Klass Naturheilkd 2004;11:150-157.
12. Lümmen G, Brinkmann OA, Luboldt HJ, Hertle L, Rübben H: Interferon-α, interleukin 2 and 5-fluorouracil versus mistletoe lectin in metastatic renal cell carcinoma - long term results (abstr). Eur Urol 2001;39(suppl 5):121.
13. Cazacu M, Oniu T, Lungoci C, Mihailov A, Cipak A, Klinger R, Weiss T, Zarkovic N: The influence of Isorel on advanced colorectal cancer. Cancer Biother Radiopharm 2003;18:27-34.
14. Piao BK, Wang YX, Xie GR, Mansmann U, Matthes H, Beuth J, Lin HS: Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res 2004;24:303-309.